MEDIGENE Trademark

Trademark Overview

On Friday, February 15, 2019, a trademark application was filed for MEDIGENE with the United States Patent and Trademark Office. The USPTO has given the MEDIGENE trademark a serial number of 88302793. The federal status of this trademark filing is REGISTERED as of Tuesday, February 28, 2023. This trademark is owned by Medigene AG. The MEDIGENE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Services in the field of molecular biology, namely, research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds and tumor antigens with pharmaceutical properties; development of test methods and test kits in the field of molecular biology; development of adoptive T cell therapy; development of DC vaccines; development of cellular tumor therapy; development of tumor markers; development of diagnostic and therapeutic antibodies; genetic and biological cell analyses; development of individualized medicine, development of treatment plans and therapy adapted for individual patients; all the foregoing being for scientific purposes
medigene

General Information

Serial Number88302793
Word MarkMEDIGENE
Filing DateFriday, February 15, 2019
Status700 - REGISTERED
Status DateTuesday, February 28, 2023
Registration Number6991921
Registration DateTuesday, February 28, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 12, 2019

Trademark Statements

Goods and ServicesServices in the field of molecular biology, namely, research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds and tumor antigens with pharmaceutical properties; development of test methods and test kits in the field of molecular biology; development of adoptive T cell therapy; development of DC vaccines; development of cellular tumor therapy; development of tumor markers; development of diagnostic and therapeutic antibodies; genetic and biological cell analyses; development of individualized medicine, development of treatment plans and therapy adapted for individual patients; all the foregoing being for scientific purposes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, March 8, 2019
Primary Code042
First Use Anywhere DateThursday, September 29, 2016
First Use In Commerce DateThursday, September 29, 2016

Trademark Owner History

Party NameMedigene AG
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressPlanegg-Martinsried 82152
DE
Party NameMedigene AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressPlanegg-Martinsried 82152
DE
Party NameMedigene AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressPlanegg-Martinsried 82152
DE

Trademark Events

Event DateEvent Description
Tuesday, February 28, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, February 28, 2023REGISTERED-PRINCIPAL REGISTER
Thursday, January 26, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, January 25, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, January 18, 2023STATEMENT OF USE PROCESSING COMPLETE
Wednesday, January 4, 2023USE AMENDMENT FILED
Wednesday, January 4, 2023TEAS STATEMENT OF USE RECEIVED
Saturday, July 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 8, 2022SOU EXTENSION 5 GRANTED
Tuesday, June 28, 2022SOU EXTENSION 5 FILED
Tuesday, June 28, 2022TEAS EXTENSION RECEIVED
Thursday, January 6, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 4, 2022SOU EXTENSION 4 GRANTED
Tuesday, January 4, 2022SOU EXTENSION 4 FILED
Tuesday, January 4, 2022TEAS EXTENSION RECEIVED
Friday, December 17, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 17, 2021TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Friday, December 17, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, December 17, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 15, 2021SOU EXTENSION 3 GRANTED
Tuesday, July 6, 2021SOU EXTENSION 3 FILED
Tuesday, July 6, 2021TEAS EXTENSION RECEIVED
Monday, March 29, 2021ASSIGNED TO EXAMINER
Wednesday, January 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 12, 2021SOU EXTENSION 2 GRANTED
Tuesday, December 22, 2020SOU EXTENSION 2 FILED
Tuesday, December 22, 2020TEAS EXTENSION RECEIVED
Wednesday, August 5, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 4, 2020SOU EXTENSION 1 GRANTED
Tuesday, July 7, 2020SOU EXTENSION 1 FILED
Tuesday, August 4, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 7, 2020TEAS EXTENSION RECEIVED
Tuesday, January 7, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 12, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 23, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, October 4, 2019ASSIGNED TO LIE
Tuesday, October 1, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 30, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, September 28, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, September 28, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 29, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 29, 2019NON-FINAL ACTION E-MAILED
Friday, March 29, 2019NON-FINAL ACTION WRITTEN
Wednesday, March 20, 2019ASSIGNED TO EXAMINER
Friday, March 8, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 19, 2019NEW APPLICATION ENTERED

Related Keywords

medigene development field therapy tumor molecular test biological methods treatment cell